• 1. Amide linked redox-active naphthoquinones for the treatment of mitochondrial dysfunction
  Krystel L. Woolley,Monila Nadikudi,Mitra N. Koupaei,Monika Corban,Paul McCartney,Alex C. Bissember,Trevor W. Lewis,Nuri Gueven,Jason A. Smith Med. Chem. Commun. 2019 10 399
• 2. In vitro study of polydopamine nanoparticles as protective antioxidant agents in fibroblasts derived from ARSACS patients
  Matteo Battaglini,Alessio Carmignani,Chiara Martinelli,Jamila Colica,Attilio Marino,Stefano Doccini,Valentina Mollo,Francesca Santoro,Martina Bartolucci,Andrea Petretto,Filippo Maria Santorelli,Gianni Ciofani Biomater. Sci. 2022 10 3770
• 3. AgNO3-catalyzed decarboxylative cross-coupling reaction: an approach to coenzyme Q
  Wan-Yue Luo,Bin Lu,Yong-Fu Qiu,Rong-Ye Zhou,Yong-Jing He,Jin Wang New J. Chem. 2020 44 8702
• 4. Recent advances in small molecules for improving mitochondrial disorders
  Liying Meng,Guanzhao Wu RSC Adv. 2023 13 20476
• 5. Metal-rich cascade nanosystem for dual-pathway ferroptosis resistance regulation and photothermal effect for efficient tumor combination therapy
  Xinran Liu,Ping Guan,Jiaxiang Mu,Zhaoxu Meng,He Lian Biomater. Sci. 2023 11 3906

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Prenylquinones
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Quinone and hydroquinone lipids Prenylquinones
• Other Chemical Reagents

Idebenone (CAS No. 58186-27-9): A Comprehensive Overview of Its Mechanism, Applications, and Recent Research Findings

The compound Idebenone, with the chemical name 2,3-dimethoxy-5-methyl-1,4-benzoquinone, is a synthetic derivative of coenzyme Q10. It is widely recognized for its potential neuroprotective and antioxidant properties. The CAS No. 58186-27-9 uniquely identifies this molecule in the chemical database, underscoring its significance in pharmaceutical and biotechnological research. Idebenone has garnered considerable attention due to its ability to mitigate oxidative stress and enhance mitochondrial function, making it a promising candidate for treating various neurological disorders.

Idebenone operates primarily by scavenging reactive oxygen species (ROS) and improving ATP production in mitochondria. This mechanism is particularly relevant in conditions where mitochondrial dysfunction plays a pivotal role, such as in neurodegenerative diseases like Alzheimer's and Parkinson's. Recent studies have highlighted the compound's efficacy in enhancing cognitive functions and reducing oxidative damage in neuronal cells. For instance, a 2022 study published in the *Journal of Neurochemistry* demonstrated that Idebenone could significantly reduce oxidative stress-induced neuronal death in vitro, suggesting its potential as a therapeutic agent.

The pharmacokinetic profile of Idebenone has also been extensively studied to optimize its therapeutic efficacy. Unlike coenzyme Q10, which has a relatively short half-life due to rapid metabolism by the liver, Idebenone exhibits better bioavailability and longer circulation time. This property makes it a more viable option for clinical applications. Furthermore, research has shown that Idebenone can cross the blood-brain barrier, a crucial factor for treating central nervous system disorders. A 2021 review article in *Pharmaceuticals* outlined several preclinical trials where Idebenone demonstrated significant improvements in motor function and cognitive decline in animal models of Parkinson's disease.

Recent advancements in nanotechnology have also opened new avenues for delivering Idebenone more effectively. Nanoparticle-based drug delivery systems have been explored to enhance the compound's penetration into target tissues and reduce side effects. For example, liposomes and polymeric nanoparticles have been investigated as carriers for Idebenone, showing promise in targeted drug delivery to mitochondria. These innovations could potentially revolutionize the treatment of neurological disorders by ensuring higher concentrations of the active compound reach the affected areas.

The therapeutic potential of Idebenone extends beyond neurodegenerative diseases. Studies have also explored its role in treating mitochondrial myopathies, a group of disorders characterized by muscle weakness due to impaired mitochondrial energy production. A clinical trial conducted by researchers at the University of California found that patients treated with Idebenone exhibited modest improvements in muscle strength and endurance compared to placebo groups. While further research is needed to confirm these findings, they highlight the compound's broad therapeutic spectrum.

From a chemical perspective, Idebenone's structure allows it to interact with various biological targets beyond just ROS scavenging. It can modulate mitochondrial calcium handling and activate ATP-sensitive potassium channels, which are crucial for maintaining cellular homeostasis. These multifaceted mechanisms contribute to its diverse therapeutic applications. Additionally, recent studies have begun to explore the potential synergistic effects of combining Idebenone with other antioxidants or neuroprotective agents. Such combinations could lead to more robust therapeutic outcomes by targeting multiple pathways involved in oxidative stress and mitochondrial dysfunction.

The safety profile of Idebenone has been another focus of recent research efforts. While generally well-tolerated at therapeutic doses, some studies have reported mild side effects such as gastrointestinal discomfort or headaches. Long-term studies are essential to fully understand the compound's safety profile across different populations and disease states. Regulatory agencies continue to monitor these developments closely to ensure that clinical applications of Idebenone are both safe and effective.

In conclusion, Idebenone (CAS No. 58186-27-9) represents a significant advancement in the treatment of neurological disorders due to its potent antioxidant properties and ability to improve mitochondrial function. The latest research findings underscore its potential as a therapeutic agent for conditions ranging from neurodegenerative diseases to mitochondrial myopathies. As further studies continue to elucidate its mechanisms of action and optimize delivery systems, Idebenone is poised to play an increasingly important role in modern medicine.

• 303-98-0(coenzyme Q10)
• 24663-35-2(Coenzyme Q11)
• 27696-12-4(2,5-Cyclohexadiene-1,4-dione,2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyl-2,6,10,14,18,22,26,30,34,38-tetracontadecaen-1-yl]-5,6-dimethoxy-3-methyl-,radical ion(1-))
• 14599-49-6(2-Decaprenyl-3-methyl-6-methoxy-1,4-benzoquinone)
• 303-95-7(Coenzyme Q7)
• 303-97-9(Coenzyme Q9)
• 1173-76-8(2,5-Cyclohexadiene-1,4-dione,2,3-dimethoxy-5-methyl-6-[(2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl]-)
• 1065-31-2(Ubiquinone-30)
• 2394-68-5(Coenzyme Q8)
• 25222-34-8(2,5-Cyclohexadiene-1,4-dione,2-(3,7,11,15,19,23,27-heptamethyl-2,6,10,14,18,22,26-octacosaheptadienyl)-5,6-dimethoxy-3-methyl-,(Z,E,E,E,E,E)- (9CI))